Amanote Research
Register
Sign In
Combination Immunotherapy With Clinical-Scale Enriched Human T Cells, Hu14.18 Antibody, and the Immunocytokine Fc-Il7 in Disseminated Neuroblastoma
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-05-1184
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
December 1, 2005
Authors
M. Otto
Publisher
American Association for Cancer Research (AACR)
Related search
Immunogenicity of the Hu14.18-Il2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
Clinical Cancer Research
Cancer Research
Oncology
Anti-Cd105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-Gd2 Antibody Immunotherapy of Neuroblastoma With Activated Natural Killer Cells
Clinical Cancer Research
Cancer Research
Oncology
Adoptive Cancer Immunotherapy With Human Vγ2vδ2 T Cells
Mechanisms of the Antitumor Activity of Human Vγ9Vδ2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Inducible Gene Switches With Memory in Human T Cells for Cellular Immunotherapy
Normal Human Serum Contains a Natural IgM Antibody Cytotoxic for Human Neuroblastoma Cells.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies—A Validation Study
PLoS ONE
Multidisciplinary
Development of Next Generation Antibody-Based Immunotherapy for Childhood Cancer Neuroblastoma
The Lancet
Medicine
Regulatory T Cells in Cancer Immunotherapy
Current Opinion in Immunology
Allergy
Immunology
